MAY 09, 2017 07:00 AM PDT
WEBINAR: Advanced assays for high-throughput assessment of ion channel inhibition and cardiac toxicity
SPONSORED BY: Molecular Devices
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
6 9 1613

Speakers:
  • Field Applications Scientist, Molecular Devices
    Biography
      Beiyan Zou is a Field Applications Scientist at Molecular Devices supporting reagents, FlexStation3, FLIPR and automated electrophysiology platforms. She received a Ph.D. degree in Biology at Pennsylvania State University and completed postdoctoral training in the Department of Neuroscience at John Hopkins University School of Medicine. She has 18 years of experience in molecular biology/genetics, 8 years of experience in ion channel biology, 4 years of experience in cellular imaging, and 8 years of experience in assay development and high throughput screen including 5 years of experience as a project leader at the Johns Hopkins Ion Channel Center, one of the nine NIH roadmap program funded screening centers. She has authored and coauthored in 20 peer-review papers in prestigious journals including PNAS, Cell, Journal of Neuroscience, Molecular Pharmacology and Assay Drug Development Technologies.
    • Research Scientist, Molecular Devices
      Biography
        Oksana Sirenko is a Research Scientist at Molecular Devices working on development of new technologies for imaging and high content analysis. Oksana also has previous experience working on drug discovery and drug development at several biotech companies in San Francisco Bay Area. The focus of her current scientific research is on development methods for high throughput in vitro toxicity screening, including 3D models. Oksana has a PhD in Biochemistry and B.S. in Biology.

      Abstract:

      DATE: May 9th, 2017
      TIME: 7:00AM PDT, 10:00AM ET, 2:00PM GMT

       

      Early detection and elimination of new chemical entities with cardiac or hERG liability could substantially improve drug safety and minimize the cost of development. In this webinar, we will highlight different assays for validating ion channel inhibition using cell lines and cardiac toxicity using induced pluripotent stem cells (iPSCs).

      High-throughput screening for in vitro potency evaluation of cardiac ion channel inhibitors on the FLIPR Tetra® System

      Learning Objectives:

      • Optimize and validate a robust cell-based hERG fluorescence assay using the FLIPR® Potassium Assay Kit, a thallium-sensitive fluorescence dye to directly measure ion influx
      • Run inhibition assays with voltage-gated sodium channels (NaV1.5) and L-type voltage-gated calcium channels (CaV1.2) using FLIPR® Membrane Potential Dye and FLIPR® Calcium 6 Dye, respectively
      • Demonstrate high-throughput, early stage in vitro compound and potency assessment with comparable results from electrophysiological recording data

       

      Multi-parameter in vitro assessment of compound effects on cardiomyocyte physiology using induced pluripotent stem cells

      Learning Objectives:

      • Determine the effects of pharmacological compounds and other chemicals on the beating rate and profiles of cardiomyocytes using the FLIPR Tetra system and ImageXpress® Micro system. Assay data is characterized from 2D and 3D spheroid cardiomyocyte cultures. The assays employ calcium sensitive dyes to monitor changes in intracellular Ca2+ fluxes synchronous with cell beating which allows monitoring of beat rate, amplitude, and other parameters.
      • Identify methods for multiparametric analysis and ranking of compounds for potential cardiotoxic hazards. This methodology is well suited for testing environmental chemicals and early safety testing in drug development prior to clinical studies.

       


      Show Resources
      Loading Comments...